Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAC002
- Development stage
- Unknown
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DAC002 is an antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotech that targets the trophoblast cell-surface antigen 2 (Trop-2). Trop-2 is a cell-surface glycoprotein that is highly expressed in a variety of epithelial carcinomas, including triple-negative breast cancer (TNBC) and small cell lung cancer (SCLC), while showing limited expression in normal tissues. The ADC is designed to bind specifically to Trop-2, leading to internalization of the complex and subsequent intracellular release of a cytotoxic payload to induce cell death. DAC002 received clinical trial approval from the China National Medical Products Administration (NMPA) in July 2020 for the treatment of solid malignant tumors and is currently undergoing Phase 1 clinical evaluation.
- Other names
- Trop-2-ADCTrop2-ADCTrop 2-ADC
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on DAC002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAC002.